{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:22:07Z","timestamp":1791404527880,"version":"4.3.3"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"NIH National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R01GM137135"],"award-info":[{"award-number":["R01GM137135"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Microbiology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.mib.2025.102630","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T18:40:30Z","timestamp":1752604830000},"page":"102630","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Recent advances in natural and synthetic phosphonate therapeutics"],"prefix":"10.1016","volume":"87","author":[{"given":"Jerry","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0438-6740","authenticated-orcid":false,"given":"Kou-San","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mib.2025.102630_bib1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev.biochem.78.091707.100215","article-title":"Biosynthesis of phosphonic and phosphinic acid natural products","volume":"78","author":"Metcalf","year":"2009","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.mib.2025.102630_sbref2","doi-asserted-by":"crossref","first-page":"12175","DOI":"10.1073\/pnas.1500873112","article-title":"Discovery of phosphonic acid natural products by mining the genomes of 10,000 actinomycetes","volume":"112","author":"Ju","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.mib.2025.102630_bib3","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1021\/acschembio.0c00256","article-title":"Genome mining reveals the phosphonoalamide natural products and a new route in phosphonic acid biosynthesis","volume":"15","author":"Kayrouz","year":"2020","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.mib.2025.102630_bib4","doi-asserted-by":"crossref","DOI":"10.1128\/aem.00338-23","article-title":"Discovery of antimicrobial phosphonopeptide natural products from Bacillus velezensis by genome mining","volume":"89","author":"Wilson","year":"2023","journal-title":"Appl Environ Microbiol"},{"key":"10.1016\/j.mib.2025.102630_sbref5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/mBio.03402-20","article-title":"A phosphonate natural product made by Pantoea ananatis is necessary and sufficient for the hallmark lesions of onion center rot","volume":"12","author":"Polidore","year":"2021","journal-title":"mBio"},{"key":"10.1016\/j.mib.2025.102630_bib6","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1021\/acssynbio.6b00299","article-title":"Discovery of a phosphonoacetic acid derived natural product by pathway refactoring","volume":"6","author":"Freestone","year":"2017","journal-title":"ACS Synth Biol"},{"key":"10.1016\/j.mib.2025.102630_bib7","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41429-021-00444-z","article-title":"Fosfomycin and nitrofurantoin: classic antibiotics and perspectives","volume":"74","author":"Dos Santos","year":"2021","journal-title":"J Antibiot"},{"key":"10.1016\/j.mib.2025.102630_bib8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s10295-013-1375-2","article-title":"Genomics-enabled discovery of phosphonate natural products and their biosynthetic pathways","volume":"41","author":"Ju","year":"2014","journal-title":"J Ind Microbiol Biotechnol"},{"key":"10.1016\/j.mib.2025.102630_bib9","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41589-019-0343-1","article-title":"Fosmidomycin biosynthesis diverges from related phosphonate natural products","volume":"15","author":"Parkinson","year":"2019","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.mib.2025.102630_bib10","first-page":"521","article-title":"Fosmidomycin, a new phosphonic acid antibiotic. Part II: 1. Human pharmacokinetics. 2. Preliminary early phase IIa clinical studies","volume":"23","author":"Kuemmerle","year":"1985","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"10.1016\/j.mib.2025.102630_bib11","first-page":"515","article-title":"Fosmidomycin: a new phosphonic acid antibiotic. Part I: Phase I tolerance studies","volume":"23","author":"Kuemmerle","year":"1985","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"10.1016\/j.mib.2025.102630_bib12","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1126\/science.285.5433.1573","article-title":"Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs","volume":"285","author":"Jomaa","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.mib.2025.102630_bib13","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0140-6736(02)11860-5","article-title":"Fosmidomycin for malaria","volume":"360","author":"Missinou","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.mib.2025.102630_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ph15121553","article-title":"Over 40 years of fosmidomycin drug research: a comprehensive review and future opportunities","volume":"15","author":"Knak","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.mib.2025.102630_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpddr.2024.100577","article-title":"Modified dosing schedule efficacy of fosmidomycin and clindamycin against murine malaria Plasmodium berghei","volume":"27","author":"Walker","year":"2025","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"10.1016\/j.mib.2025.102630_sbref16","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1039\/D3MD00642E","article-title":"Inhibition of DXR in the MEP pathway with lipophilic N-alkoxyaryl FR900098 analogs","volume":"15","author":"Bague","year":"2024","journal-title":"RSC Med Chem"},{"key":"10.1016\/j.mib.2025.102630_bib17","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1021\/acsinfecdis.1c00132","article-title":"Characterization and inhibition of 1-Deoxy-d-Xylulose 5-phosphate reductoisomerase: a promising drug target in Acinetobacter baumannii and Klebsiella pneumoniae","volume":"7","author":"Ball","year":"2021","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.mib.2025.102630_bib18","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1021\/acsinfecdis.6b00125","article-title":"Structure-activity relationships of the MEPicides: N-Acyl and O-linked analogs of FR900098 as inhibitors of Dxr from Mycobacterium tuberculosis and Yersinia pestis","volume":"2","author":"San Jose","year":"2016","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.mib.2025.102630_bib19","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1021\/acsinfecdis.3c00132","article-title":"MEPicides: alpha,beta-unsaturated fosmidomycin N-Acyl analogs as efficient inhibitors of Plasmodium falciparum 1-Deoxy-d-xylulose-5-phosphate reductoisomerase","volume":"9","author":"Wang","year":"2023","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.mib.2025.102630_bib20","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/acsinfecdis.4c00100","article-title":"Reverse N-substituted hydroxamic acid derivatives of fosmidomycin target a previously unknown subpocket of 1-Deoxy-d-xylulose 5-phosphate reductoisomerase (DXR)","volume":"10","author":"Abdullaziz","year":"2024","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.mib.2025.102630_bib21","first-page":"12","article-title":"Studies on a new phosphonic acid antibiotic, SF-2312","volume":"25","author":"Watanabe HY","year":"1986","journal-title":"Sci Rep Meiji Seika Kaisha"},{"key":"10.1016\/j.mib.2025.102630_sbref22","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/nchembio.2195","article-title":"SF2312 is a natural phosphonate inhibitor of enolase","volume":"12","author":"Leonard","year":"2016","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.mib.2025.102630_bib23","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.3390\/molecules24132510","article-title":"The 3S enantiomer drives enolase inhibitory activity in SF2312 and its analogues","volume":"24","author":"Pisaneschi","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.mib.2025.102630_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-53301-3","article-title":"Functional and structural basis of E. coli enolase inhibition by SF2312: a mimic of the carbanion intermediate","volume":"9","author":"Krucinska","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.mib.2025.102630_bib25","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/s42255-020-00313-3","article-title":"An enolase inhibitor for the targeted treatment of ENO1-deleted cancers","volume":"2","author":"Lin","year":"2020","journal-title":"Nat Metab"},{"key":"10.1016\/j.mib.2025.102630_sbref26","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1021\/acsmedchemlett.0c00203","article-title":"Bioreducible phosphonoamidate pro-drug inhibitor of enolase: proof of concept study","volume":"11","author":"Yan","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.mib.2025.102630_bib27","doi-asserted-by":"crossref","first-page":"13813","DOI":"10.1021\/acs.jmedchem.2c01039","article-title":"Prodrugs of a 1-hydroxy-2-oxopiperidin-3-yl phosphonate Enolase inhibitor for the treatment of ENO1-deleted cancers","volume":"65","author":"Yan","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.mib.2025.102630_bib28","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1021\/acsptsci.2c00216","article-title":"Comparative pharmacology of a bis-pivaloyloxymethyl phosphonate prodrug inhibitor of enolase after oral and parenteral administration","volume":"6","author":"Yan","year":"2023","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.mib.2025.102630_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1012412","article-title":"Enolase inhibitors as therapeutic leads for Naegleria fowleri infection","volume":"20","author":"Milanes","year":"2024","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.mib.2025.102630_bib30","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.3390\/pathogens12111290","article-title":"Enolase inhibitors as early lead therapeutics against Trypanosoma brucei","volume":"12","author":"Roster","year":"2023","journal-title":"Pathogens"},{"key":"10.1016\/j.mib.2025.102630_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.116289","article-title":"Bisphosphonates: the role of chemistry in understanding their biological actions and structure-activity relationships, and new directions for their therapeutic use","volume":"156","author":"Ebetino","year":"2022","journal-title":"Bone"},{"key":"10.1016\/j.mib.2025.102630_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115222","article-title":"History of etidronate","volume":"134","author":"Watts","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.mib.2025.102630_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/s41413-023-00287-4","article-title":"Evidence of bisphosphonate-conjugated sitafloxacin eradication of established methicillin-resistant S. aureus infection with osseointegration in murine models of implant-associated osteomyelitis","volume":"11","author":"Ren","year":"2023","journal-title":"Bone Res"},{"key":"10.1016\/j.mib.2025.102630_bib34","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/207888a0","article-title":"Inhibition of encephalomyocarditis virus replication by simple phosphonic and carboxylic acids","volume":"207","author":"Kochman","year":"1965","journal-title":"Nature"},{"key":"10.1016\/j.mib.2025.102630_bib35","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1128\/am.26.3.264-267.1973","article-title":"Suppression of herpes simplex virus infection by phosphonoacetic acid","volume":"26","author":"Shipkowitz","year":"1973","journal-title":"Appl Microbiol"},{"key":"10.1016\/j.mib.2025.102630_bib36","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1021\/bi00647a029","article-title":"Mechanism of phosphonoacetate inhibition of herpesvirus-induced DNA polymerase","volume":"15","author":"Leinbach","year":"1976","journal-title":"Biochemistry"},{"key":"10.1016\/j.mib.2025.102630_bib37","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1128\/AAC.13.2.188","article-title":"Inhibition of herpesvirus replication and herpesvirus-induced deoxyribonucleic acid polymerase by phosphonoformate","volume":"13","author":"Reno","year":"1978","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2025.102630_bib38","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.210500","article-title":"Trisodium phosphonoformate, a new antiviral compound","volume":"201","author":"Helgstrand","year":"1978","journal-title":"Science"},{"key":"10.1016\/j.mib.2025.102630_bib39","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0163-7258(82)90074-2","article-title":"Antiviral effects of phosphonoformate (PFA, foscarnet sodium)","volume":"19","author":"Oberg","year":"1982","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.mib.2025.102630_bib40","series-title":"Foscarnet","author":"Garikapati SN","year":"2023"},{"key":"10.1016\/j.mib.2025.102630_bib41","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.3390\/v14091978","article-title":"The elegance of the acyclic nucleoside phosphonates (ANPs), honorary tribute to Antonin Holy, who passed away on 16 July 2012, at the 10th anniversary of his death","volume":"14","author":"De Clercq","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.mib.2025.102630_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.889737","article-title":"Phosphonates and phosphonate prodrugs in medicinal chemistry: past successes and future prospects","volume":"10","author":"Krecmerova","year":"2022","journal-title":"Front Chem"},{"key":"10.1016\/j.mib.2025.102630_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114559","article-title":"Synthesis and anti-trypanosomal evaluation of novel N-branched acyclic nucleoside phosphonates bearing 7-aryl-7-deazapurine nucleobase","volume":"239","author":"Vankova","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.mib.2025.102630_bib44","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nchembio.2007.9","article-title":"Unusual transformations in the biosynthesis of the antibiotic phosphinothricin tripeptide","volume":"3","author":"Blodgett","year":"2007","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.mib.2025.102630_bib45","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1021\/acschembio.3c00452","article-title":"Phosphonate and thiasugar analogues of glucosamine-6-phosphate: activation of the glmS riboswitch and antibiotic activity","volume":"18","author":"Silkenath","year":"2023","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.mib.2025.102630_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107767","article-title":"Exploring fluorinated heptose phosphate analogues as inhibitors of HldA and HldE, key enzymes in the biosynthesis of lipopolysaccharide","volume":"153","author":"Cao","year":"2024","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.mib.2025.102630_sbref47","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.chembiol.2024.07.006","article-title":"Mixed alkyl\/aryl phosphonates identify metabolic serine hydrolases as antimalarial targets","volume":"31","author":"Bennett","year":"2024","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.mib.2025.102630_bib48","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1039\/D3MD00286A","article-title":"alpha-Aminophosphonate inhibitors of metallo-beta-lactamases NDM-1 and VIM-2","volume":"14","author":"Palica","year":"2023","journal-title":"RSC Med Chem"},{"key":"10.1016\/j.mib.2025.102630_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115473","article-title":"Metal binding pharmacophore click-derived discovery of new broad-spectrum metallo-beta-lactamase inhibitors","volume":"257","author":"Yan","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.mib.2025.102630_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116853","article-title":"Discovery of orally bioavailable phosphonate prodrugs of potent ENPP1 inhibitors for cancer treatment","volume":"279","author":"Gao","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.mib.2025.102630_bib51","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1021\/acsmedchemlett.4c00371","article-title":"Enhanced plasma stability and potency of aryl\/acyloxy prodrugs of a BTN3A1 ligand","volume":"15","author":"Singh","year":"2024","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.mib.2025.102630_bib52","doi-asserted-by":"crossref","first-page":"14774","DOI":"10.1002\/anie.201607824","article-title":"Design of potent mannose 6-phosphate analogues for the functionalization of lysosomal enzymes to improve the treatment of Pompe disease","volume":"55","author":"El Cheikh","year":"2016","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.mib.2025.102630_bib53","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41586-020-2545-9","article-title":"Lysosome-targeting chimaeras for degradation of extracellular proteins","volume":"584","author":"Banik","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.mib.2025.102630_sbref54","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1273280","article-title":"Engineered therapeutic antibodies with mannose 6-phosphate analogues as a tool to degrade extracellular proteins","volume":"15","author":"Daurat","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.mib.2025.102630_sbref55","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202200526","article-title":"Phosphonate derivatives of paracetamol and valproic acid","volume":"18","author":"Ballok","year":"2023","journal-title":"ChemMedChem"},{"key":"10.1016\/j.mib.2025.102630_bib56","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0163-7258(79)90021-4","article-title":"The antiherpesvirus action of phosphonoacetate","volume":"4","author":"Boezi","year":"1979","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.mib.2025.102630_sbref57","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/s44160-024-00507-7","article-title":"Engineering non-haem iron enzymes for enantioselective C(sp3)-F bond formation via radical fluorine transfer","volume":"3","author":"Zhao","year":"2024","journal-title":"Nat Synth"}],"container-title":["Current Opinion in Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1369527425000529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1369527425000529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:03:10Z","timestamp":1779084190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1369527425000529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":57,"alternative-id":["S1369527425000529"],"URL":"https:\/\/doi.org\/10.1016\/j.mib.2025.102630","relation":{},"ISSN":["1369-5274"],"issn-type":[{"value":"1369-5274","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in natural and synthetic phosphonate therapeutics","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Microbiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mib.2025.102630","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102630"}}